What is CTSO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CTSO?

P/E (TTM) is n/a and 52-week range is $3.51 to $19.72 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CTSO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CTSO?

The company profile lists revenue (TTM) near $37M, net income (TTM) near $-1.82B, EPS (TTM) near $-0.29 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Cytosorbents Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Princeton, New Jersey, US, 62.8M shares outstanding, ISIN US23283X2062 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Cytosorbents Corp

$CTSO

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$3.46

-3.62%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Princeton, New Jersey and currently employs 129 full-time employees. The company went IPO on 2005-06-17. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.

Employees

129

Website

cytosorbents.com/

IPO

2005-06-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)